ArticleBioactive materials2026
Glucose/ROS-responsive and redox-gated adaptive hydrogel dressing for accelerating diabetic wound repair via synergistic cGAS/STING pathway inhibition and oxidative stress alleviation.
Article in Bioactive materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Review on Recent Progress and Clinical Translation of Self-Assembled Hydrogels in Diabetic Wound Repair.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Persistent hyperglycemia-induced mitochondrial oxidative stress causes mtDNA leakage, activating the STING signaling pathway in macrophages and eliciting sustained pro-inflammatory cytokine secretion, resulting in wound healing stagnation throughout the inflammatory phase. In this study, we developed a glucose/ROS-responsive hydrogel dressing (SG) employing dynamic crosslinking via boronate ester between chlorogenic acid (CGA)-conjugated gelatin and sodium alginate functionalized with 3-aminophenylboronic acid. Furthermore, the engineered macrophage-targeting phosphatidylserine (PS)-incorporated liposomes (HPSL), designed for the precise delivery of the STING inhibitor H151, were incorporated into the hydrogel (HPSL@SG). This hydrogel exhibits superior injectability, stretchability, self-healing properties, and adaptation to the irregular shapes of skin wounds. Upon injection into a diabetic wound, the as-prepared hydrogel disintegrated in response to elevated glucose and ROS, facilitating the on-demand release of CGA and HPSL. The CGA can directly scavenge ROS to alleviate oxidative stress, achieving a 79.9% reduction in superoxide anion levels; the HPSL specifically targets macrophages to prevent disturbance of immunologic homeostasis due to off-target effects. This process facilitates macrophage polarization towards an anti-inflammatory phenotype by inhibiting the STING signaling pathway, thereby suppressing the release of pro-inflammatory cytokines TNF-α and IL-6 and promoting the release of IL-10. The HPSL@SG hydrogel collectively enhances angiogenesis, evidenced by a 6.6-fold increase in CD31 levels and a 7.3-fold increase in VEGF levels, while also facilitating collagen deposition, with collagen content escalating from 32.6% to 69.3%. This procedure culminates in an 89.7% recovery within 10 days and nearly complete wound healing within 14 days, indicating its potential for clinical application in diabetic wound healing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.